The global coronary heart disease diagnostic imaging device market size is expected to reach USD 2.96 billion by 2030, registering a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increase in coronary diseases and deaths associated with it calls for better and early diagnosis of the condition. Precise scan interpretation and technologically advanced equipment are the factors influencing the market growth. Various imaging modalities are useful in identifying unique aspects of coronary screening. For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries. However, non-invasive techniques like single-photon computed tomography (SPECT) and positron emission tomography (PET) provide indirect information on CHD by estimating the myocardial perfusion and metabolism abnormalities that are consequent of coronary artery disease.
Technological advancement in this field had led to the development of sharp camera units consisting of gamma systems, that use semiconductor detectors of cadmium zinc telluride (CZT). This led to faster acquisition of images, reduced capture time, high image quality, and lower radiation dose (1mSv for a single injection), as compared to conventional myocardial perfusion imaging by SPECT. Further, improvements around Computed Tomography, to develop non-invasive techniques have also shown great future growth in this segment. However, economic barriers, subject literacy, and lack of medical staff hold back the implementation of such advanced techniques in real practice.
The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic. Fear of virus spread, the shift in focus on diagnosing and treating COVID-19 affected patients, reduced admission rates at hospitals for other diseases, and reduced medical staff, led to the reduction in the diagnosis of CVD. Economic setback observed by end-users also influenced the adoption of advanced techniques to effectively diagnoses coronary alterations. Further, the shutting down of manufacturing units, due to national lockdowns, halt in logistics, and reduction in salesforce also impacted the market negatively.
Nuclear medicine dominated the modality segment due to the ease of image interpretation and accuracy in detection.
Computed tomography is anticipated to experience at the fastest CAGR o vefr the forecast period, due to its advantages of early detection of even the most intricate alterations which otherwise is impossible to det4ect in the traditional SPECT technology.
Asia Pacific is anticipated to be growing at a significant CAGR over the forecast period owing to the increase in R&D activities and numerous resellers.
Please note The report will be delivered in 2-3 business days upon order notification.
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Modality
1.2.2. Regional scope
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America